These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36927958)

  • 41. Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment Regimen.
    Stroffolini G; Lazzaro A; Barco A; Pirriatore V; Vai D; Giaccone C; Nigra M; Atzori C; Trunfio M; Bonora S; Di Perri G G; Calcagno A
    J Neuroimmune Pharmacol; 2023 Dec; 18(4):551-562. PubMed ID: 37906406
    [TBL] [Abstract][Full Text] [Related]  

  • 42. What can characterization of cerebrospinal fluid escape populations teach us about viral reservoirs in the central nervous system?
    Joseph SB; Trunfio M; Kincer LP; Calcagno A; Price RW
    AIDS; 2019 Dec; 33 Suppl 2():S171-S179. PubMed ID: 31790378
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cross-Sectional and Cumulative Longitudinal Central Nervous System Penetration Effectiveness Scores Are Not Associated With Neurocognitive Impairment in a Well Treated Aging Human Immunodeficiency Virus-Positive Population in Switzerland.
    Santos GMA; Locatelli I; Métral M; Calmy A; Lecompte TD; Nadin I; Hauser C; Cusini A; Hasse B; Kovari H; Tarr P; Stoeckle M; Fux C; Di Benedetto C; Schmid P; Darling KEA; Du Pasquier R; Cavassini M;
    Open Forum Infect Dis; 2019 Jul; 6(7):ofz277. PubMed ID: 31304188
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.
    García F; Alonso MM; Romeu J; Knobel H; Arrizabalaga J; Ferrer E; Dalmau D; Ruiz I; Vidal F; Frances A; Segura F; Gomez-Sirvent JL; Cruceta A; Clotet B; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    J Acquir Immune Defic Syndr; 2000 Sep; 25(1):26-35. PubMed ID: 11064501
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cerebrospinal Fluid Viral Load Across the Spectrum of Untreated Human Immunodeficiency Virus Type 1 (HIV-1) Infection: A Cross-Sectional Multicenter Study.
    Ulfhammer G; Edén A; Antinori A; Brew BJ; Calcagno A; Cinque P; De Zan V; Hagberg L; Lin A; Nilsson S; Oprea C; Pinnetti C; Spudich S; Trunfio M; Winston A; Price RW; Gisslén M
    Clin Infect Dis; 2022 Aug; 75(3):493-502. PubMed ID: 34747481
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HIV Compartmentalization in the CNS and Its Impact in Treatment Outcomes and Cure Strategies.
    Chan P; Spudich S
    Curr HIV/AIDS Rep; 2022 Jun; 19(3):207-216. PubMed ID: 35536438
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.
    Cusini A; Vernazza PL; Yerly S; Decosterd LA; Ledergerber B; Fux CA; Rohrbach J; Widmer N; Hirschel B; Gaudenz R; Cavassini M; Klimkait T; Zenger F; Gutmann C; Opravil M; Günthard HF;
    J Acquir Immune Defic Syndr; 2013 Jan; 62(1):28-35. PubMed ID: 23018371
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.
    Marra CM; Zhao Y; Clifford DB; Letendre S; Evans S; Henry K; Ellis RJ; Rodriguez B; Coombs RW; Schifitto G; McArthur JC; Robertson K;
    AIDS; 2009 Jul; 23(11):1359-66. PubMed ID: 19424052
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of High-Dose Multi-Strain Probiotic Supplementation on Neurocognitive Performance and Central Nervous System Immune Activation of HIV-1 Infected Individuals.
    Ceccarelli G; Brenchley JM; Cavallari EN; Scheri GC; Fratino M; Pinacchio C; Schietroma I; Fard SN; Scagnolari C; Mezzaroma I; Vullo V; d'Ettorre G
    Nutrients; 2017 Nov; 9(11):. PubMed ID: 29160817
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Longitudinal analysis of CSF HIV RNA in untreated people with HIV: Identification of CSF controllers.
    Trunfio M; Tang B; Okwuegbuna O; Iudicello JE; Bharti A; Moore DJ; Gelman BB; Morgello S; Patel PB; Rubin LH; Ances BM; Gianella S; Heaton RK; Ellis RJ; Letendre SL
    J Med Virol; 2024 Mar; 96(3):e29550. PubMed ID: 38511593
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Blood-Brain Barrier Impairment in Patients Living with HIV: Predictors and Associated Biomarkers.
    Caligaris G; Trunfio M; Ghisetti V; Cusato J; Nigra M; Atzori C; Imperiale D; Bonora S; Di Perri G; Calcagno A
    Diagnostics (Basel); 2021 May; 11(5):. PubMed ID: 34065785
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cerebrospinal fluid immune markers and HIV-associated neurocognitive impairments: A systematic review.
    Williams ME; Stein DJ; Joska JA; Naudé PJW
    J Neuroimmunol; 2021 Sep; 358():577649. PubMed ID: 34280844
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities: is it time to assess the definitions?
    Trunfio M; Pinnetti C; Focà E; Bai F; Maffongelli G; Celani L; Cinque P; Celotti A; Andreoni M; D'Arminio Monforte A; D'Ettorre G; Antinori A; Calcagno A
    AIDS; 2019 Mar; 33(4):759-762. PubMed ID: 30531317
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical and viro-immunological correlates of HIV associated neurocognitive disorders (HAND) in a cohort of antiretroviral-naïve HIV-infected patients.
    Bai F; Iannuzzi F; Merlini E; Borghi L; Tincati C; Trunfio M; Bini T; Monforte AD; Marchetti G
    AIDS; 2017 Jan; 31(2):311-314. PubMed ID: 28005574
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HIV-1 RNA levels in cerebrospinal fluid and plasma and their correlation with opportunistic neurological diseases in a Brazilian AIDS reference hospital.
    Christo PP; Greco DB; Aleixo AW; Livramento JA
    Arq Neuropsiquiatr; 2005 Dec; 63(4):907-13. PubMed ID: 16400403
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Concentrations of human immunodeficiency virus type 1 (HIV-1) RNA in cerebrospinal fluid after antiretroviral treatment initiated during primary HIV-1 infection.
    Enting RH; Prins JM; Jurriaans S; Brinkman K; Portegies P; Lange JM
    Clin Infect Dis; 2001 Apr; 32(7):1095-9. PubMed ID: 11264039
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Low-Level HIV RNA in Cerebrospinal Fluid and Neurocognitive Performance: A Longitudinal Cohort Study.
    Anderson AM; Tang B; Vaida F; Mcclernon D; Deutsch R; Cherner M; Cookson D; Crescini M; Grant I; Ellis RJ; Letendre SL
    J Acquir Immune Defic Syndr; 2021 Aug; 87(5):1196-1204. PubMed ID: 33901102
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy.
    Ferretti F; Gisslen M; Cinque P; Price RW
    Curr HIV/AIDS Rep; 2015 Jun; 12(2):280-8. PubMed ID: 25860317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV.
    Hammond ER; Crum RM; Treisman GJ; Mehta SH; Marra CM; Clifford DB; Morgello S; Simpson DM; Gelman BB; Ellis RJ; Grant I; Letendre SL; McArthur JC;
    Am J Epidemiol; 2014 Aug; 180(3):297-307. PubMed ID: 24966216
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.
    Letendre SL; Mills AM; Tashima KT; Thomas DA; Min SS; Chen S; Song IH; Piscitelli SC;
    Clin Infect Dis; 2014 Oct; 59(7):1032-7. PubMed ID: 24944232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.